Sep 10 |
Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma
|
Aug 9 |
Arcellx GAAP EPS of -$0.51, revenue of $27.38M
|
Aug 8 |
Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates
|
Aug 8 |
Arcellx Provides Second Quarter 2024 Financial Results and Business Updates
|
Aug 2 |
Here’s Why Arcellx (ACLX) Slipped in Q2
|
Aug 2 |
A Look At The Intrinsic Value Of Arcellx, Inc. (NASDAQ:ACLX)
|
Jul 24 |
Alkermes Lags Q2 Earnings Estimates
|
Jul 4 |
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
|
Jun 29 |
Insider Sale: CFO Michelle Gilson Sells 12,877 Shares of Arcellx Inc (ACLX)
|
Jun 26 |
Arcellx's Strategic Moves With Anito-Cel Aim To Disrupt Myeloma Market
|